Find Pridinol manufacturers, exporters & distributors on PharmaCompass

Pridinol

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

4 API Suppliers, 1 JDMF, 1 EU WC, 2 Listed Suppliers

4 API Suppliers
1 JDMF
1 EU WC
2 Listed Suppliers

FINISHED DOSAGE FORMULATIONS

1 FDF Dossiers, 1 Listed Dossiers

1 FDF Dossiers
1 Listed Dossiers

MARKET PLACE

10 APIs, 1 FDF Dossiers

marketPlace
10 APIs
1 FDF Dossiers

ANALYTICAL

2 BioAnalytical Methods

otherMethods
2 BioAnalytical Methods

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 701

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 511-45-5, 1,1-diphenyl-3-(piperidin-1-yl)propan-1-ol, Nonplesin, Lyseen, Parks, Parks 12

Molecular Formula

C₂₀H₂₅NO

Molecular Weight

295.4 g/mol

InChI Key

RQXCLMGKHJWMOA-UHFFFAOYSA-N

FDA UNII

9E75Q6SUUB

1 2D Structure

Pridinol

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

1,1-diphenyl-3-piperidin-1-ylpropan-1-ol

2.1.2 InChI

InChI=1S/C20H25NO/c22-20(18-10-4-1-5-11-18,19-12-6-2-7-13-19)14-17-21-15-8-3-9-16-21/h1-2,4-7,10-13,22H,3,8-9,14-17H2

2.1.3 InChI Key

RQXCLMGKHJWMOA-UHFFFAOYSA-N

2.1.4 Canonical SMILES

C1CCN(CC1)CCC(C2=CC=CC=C2)(C3=CC=CC=C3)O

2.2 Other Identifiers

2.2.1 UNII

9E75Q6SUUB

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 3-(n-piperidinyl)-1,1-diphenyl-1-propanol Methanesulfonate

2. 3-piperidino-1,1-diphenylpropanol

3. 3-piperidinyl-1,1-diphenylpropan-1-ol

4. Myoson

5. Pridinol Mesylate

6. Pridinol Monohydrochloride

7. Pridinol Monomesylate

8. Ridinol

2.3.2 Depositor-Supplied Synonyms

1. 511-45-5

2. 1,1-diphenyl-3-(piperidin-1-yl)propan-1-ol

3. Nonplesin

4. Lyseen

5. Parks

6. Parks 12

7. Parks 12 Hommel

8. Pridinolum

9. Nonpressin (free Base)

10. C-238

11. Hh 212

12. 1,1-diphenyl-3-piperidino-1-propanol

13. Alpha,alpha-diphenyl-1-piperidinepropanol

14. 1,1-diphenyl-3-(1-piperidyl)-1-propanol

15. 1-piperidinepropanol, Alpha,alpha-diphenyl-

16. 3-(n-piperidyl)-1,1-diphenyl-1-propanol

17. 238 C

18. Nsc 23016

19. Nsc-23016

20. Nsc23016

21. 9e75q6suub

22. 1,1-diphenyl-3-piperidin-1-ylpropan-1-ol

23. 1,1-diphenyl-3-(1-piperidinyl)-1-propanol

24. Ridinol

25. Chebi:75247

26. Pridinol (inn)

27. Pridinol Mesilate

28. Benzhydrol, .alpha.-(2-piperidinoethyl)-

29. Pridinol [inn]

30. Nsc 23016; Nsc 403797; Nonplesin

31. .alpha.,.alpha.-diphenyl-1-piperidinepropanol

32. Dsstox_cid_25090

33. Dsstox_rid_80664

34. Dsstox_gsid_45090

35. Pridinol [inn:dcf]

36. Pridinolum [inn-latin]

37. 1-piperidinepropanol,.alpha.-diphenyl-

38. Cas-511-45-5

39. Hsdb 2684

40. Einecs 208-128-0

41. Unii-9e75q6suub

42. Benzhydrol, Alpha-(2-piperidinoethyl)-

43. Brn 0252983

44. A-carotene

45. Spectrum_001320

46. Pridinol [hsdb]

47. Pridinol [mi]

48. Prestwick0_000799

49. Prestwick1_000799

50. Prestwick2_000799

51. Prestwick3_000799

52. Spectrum2_001985

53. Spectrum3_001552

54. Spectrum4_000728

55. Spectrum5_001069

56. Pridinol [who-dd]

57. Ncistruc1_000328

58. Ncistruc2_000375

59. Bspbio_000938

60. Bspbio_003024

61. Kbiogr_000996

62. Kbioss_001800

63. 5-20-02-00247 (beilstein Handbook Reference)

64. Divk1c_000726

65. Schembl143298

66. Spbio_002169

67. Spbio_002877

68. Bpbio1_001032

69. Chembl404215

70. Dtxsid0045090

71. Kbio1_000726

72. Kbio2_001800

73. Kbio2_004368

74. Kbio2_006936

75. Kbio3_002524

76. Ninds_000726

77. Alpha-(2-piperidinoethyl)benzhydrol

78. Nci23016

79. Zinc1482149

80. Tox21_110022

81. Ccg-37974

82. Mfcd00242961

83. Ncgc00013289

84. Nsc403797

85. Akos016001547

86. Tox21_110022_1

87. Db13642

88. Nsc-403797

89. Idi1_000726

90. Ncgc00013289-01

91. Ncgc00013289-02

92. Ncgc00013289-03

93. Ncgc00013289-04

94. Ncgc00013289-05

95. Ncgc00013289-06

96. Ncgc00013289-07

97. Ncgc00013289-09

98. Ncgc00023906-03

99. Ncgc00023906-04

100. Ncgc00023906-05

101. Ac-24366

102. Nci60_001871

103. Sbi-0051765.p002

104. Ab00053638

105. 1,1-diphenyl-3-piperidin-1-yl-propan-1-ol

106. D08418

107. 1,1-diphenyl-3-(1-piperidinyl)-1-propanol #

108. 1-piperidinepropanol, .alpha.,.alpha.-diphenyl-

109. Ab00053638_16

110. Ab00053638_17

111. N-propanol, 1,1-diphenyl-3-(piperidin-1-yl)-

112. Ag-680/20240026

113. Q827515

114. Brd-k17565903-066-05-8

115. Brd-k17565903-066-15-7

2.4 Create Date

2005-03-25

3 Chemical and Physical Properties

Molecular Formula	C₂₀H₂₅NO
Molecular Weight	295.4 g/mol
XLogP3	3.8
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	2
Rotatable Bond Count	5
Exact Mass	295.193614421 g/mol
Monoisotopic Mass	295.193614421 g/mol
Topological Polar Surface Area	23.5 Å²
Heavy Atom Count	22
Formal Charge	0
Complexity	294
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Therapeutic Uses

/EXPL THER/ A randomized, double-blind, placebo-controlled three-way cross-over study was performed to investigate the effect of two muscle relaxants (tolperisone hydrochloride and pridinol mesilate) on experimental jaw-muscle pain and jaw-stretch reflexes. Fifteen healthy men participated in three randomized sessions separated by at least 1 week. In each session 300 mg tolperisone, 8 mg pridinol mesilate or placebo was administered orally as a single dose. One hour after drug administration 0.3 mL hypertonic saline (5.8%) was injected into the right masseter to produce muscle pain. Subjects continuously rated their perceived pain intensity on an electronic 10-cm visual analogue scale (VAS). The pressure pain threshold (PPT) was measured and short-latency reflex responses were evoked in the pre-contracted (15% maximal voluntary contraction) masseter and temporalis muscles by a standardised stretch device (1 mm displacement, 10 ms ramp time) before (baseline), 1 hr after medication (post-drug), during ongoing experimental muscle pain (pain-post-drug), and 15 min after pain had vanished (post-pain). Analysis of variance demonstrated significantly lower VAS peak pain scores (5.9 +/- 0.4 cm) after administration of tolperisone hydrochloride compared with pridinol mesilate (6.8 +/- 0.4 cm) and placebo (6.6 +/- 0.4 cm) (P=0.020). Administration of pridinol mesilate was associated with a significant decrease in PPTs compared with tolperisone hydrochloride and placebo (P=0.002) after medication, but not after experimental jaw-muscle pain. The normalized peak-to-peak amplitude of the stretch reflexes were not significantly influenced by the test medication (P=0.762), but were in all sessions significantly facilitated during ongoing experimental jaw-muscle pain (P=0.034). In conclusion, tolperisone hydrochloride provides a small, albeit significant reduction in the perceived intensity of experimental jaw-muscle pain whereas the present dose had no effect on the short-latency jaw-stretch reflex. /Tolperisone hydrochloride and pridinol mesilate/

PMID:12935797 Svensson P et al; Eur J Pain 7 (5): 449-56 (2003)

5 Pharmacology and Biochemistry

5.1 ATC Code

M - Musculo-skeletal system

M03 - Muscle relaxants

M03B - Muscle relaxants, centrally acting agents

M03BX - Other centrally acting agents

M03BX03 - Pridinol

API SUPPLIERS